Literature DB >> 18688035

Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration.

Nasim Shweke1, Nada Boulos, Chantal Jouanneau, Sophie Vandermeersch, Gerry Melino, Jean-Claude Dussaule, Christos Chatziantoniou, Pierre Ronco, Jean-Jacques Boffa.   

Abstract

Renal fibrosis is defined by the exaggerated accumulation of extracellular matrix proteins. Tissue transglutaminase (TG2) modifies the stability of extracellular matrix proteins and renders the extracellular matrix resistant to degradation. In addition, TG2 also activates transforming growth factor-beta (TGF-beta). We investigated the involvement of TG2 in the development of renal fibrosis using mice with a knockout of the TG2 gene (KO). These mice were studied at baseline and 12 days after unilateral ureteral obstruction, which induced a significant increase in interstitial TG2 expression in wild-type mice (P < 0.001). Interstitial fibrosis was evident in both groups, but total and fibrillar collagen was considerably lower in KO mice as compared with wild-type (P < 0.001). Similarly, mRNA and protein expression of collagen I were significantly lower in KO animals (P < 0.05). A statistically significant reduction in renal inflammation and fewer myofibroblasts were observed in KO mice (P < 0.01). Free active TGF-beta was decreased in KO mice (P < 0.05), although total (active + latent) TFG-beta concentration did not differ between groups. These results show that mice deficient in TG2 are protected against the development of fibrotic lesions in obstructive nephropathy. This protection results from reduced macrophage and myofibroblast infiltration, as well as from a decreased rate of collagen I synthesis because of decreased TGF-beta activation. Our results suggest that inhibition of TG2 may provide a new and important therapeutic target against the progression of renal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688035      PMCID: PMC2527082          DOI: 10.2353/ajpath.2008.080025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications.

Authors:  N J Skill; M Griffin; A M El Nahas; T Sanai; J L Haylor; M Fisher; M F Jamie; N N Mould; T S Johnson
Journal:  Lab Invest       Date:  2001-05       Impact factor: 5.662

Review 2.  Making sense of latent TGFbeta activation.

Authors:  Justin P Annes; John S Munger; Daniel B Rifkin
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

3.  Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism.

Authors:  J J Boffa; P L Tharaux; S Placier; R Ardaillou; J C Dussaule; C Chatziantoniou
Journal:  Circulation       Date:  1999-11-02       Impact factor: 29.690

4.  Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta.

Authors:  Fadi Fakhouri; Sandrine Placier; Raymond Ardaillou; Jean-Claude Dussaule; Christos Chatziantoniou
Journal:  J Am Soc Nephrol       Date:  2001-12       Impact factor: 10.121

Review 5.  Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction.

Authors:  Neil G Docherty; Orfhlaith E O'Sullivan; Declan A Healy; John M Fitzpatrick; R William G Watson
Journal:  Am J Physiol Renal Physiol       Date:  2006-01

6.  Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin.

Authors:  S S Akimov; A M Belkin
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

7.  Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction.

Authors:  Y Isaka; M Tsujie; Y Ando; H Nakamura; Y Kaneda; E Imai; M Hori
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

Review 9.  Transglutaminase 2: an enigmatic enzyme with diverse functions.

Authors:  Laszlo Fesus; Mauro Piacentini
Journal:  Trends Biochem Sci       Date:  2002-10       Impact factor: 13.807

10.  Gene disruption of tissue transglutaminase.

Authors:  V De Laurenzi; G Melino
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

View more
  56 in total

1.  Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.

Authors:  Laila Dafik; Chaitan Khosla
Journal:  Chem Biol       Date:  2011-01-28

Review 2.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

Review 3.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

4.  TGF-beta receptor deletion in the renal collecting system exacerbates fibrosis.

Authors:  Leslie Gewin; Nada Bulus; Glenda Mernaugh; Gilbert Moeckel; Raymond C Harris; Harold L Moses; Ambra Pozzi; Roy Zent
Journal:  J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 10.121

5.  Tissue transglutaminase inhibits the TRPV5-dependent calcium transport in an N-glycosylation-dependent manner.

Authors:  Sandor Boros; Qi Xi; Henrik Dimke; Annemiete W van der Kemp; Kukiat Tudpor; Sjoerd Verkaart; Kyu Pil Lee; René J Bindels; Joost G Hoenderop
Journal:  Cell Mol Life Sci       Date:  2011-09-28       Impact factor: 9.261

6.  Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney.

Authors:  Chi Hua Sarah Lin; Jun Chen; Zhongtao Zhang; Gail V W Johnson; Arthur J L Cooper; Julianne Feola; Alexander Bank; Jonathan Shein; Heli J Ruotsalainen; Taina A Pihlajaniemi; Michael S Goligorsky
Journal:  Kidney Int       Date:  2016-04-14       Impact factor: 10.612

7.  A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain.

Authors:  Che-Yi Chou; Andrew J Streets; Philip F Watson; Linghong Huang; Elisabetta A M Verderio; Timothy S Johnson
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

8.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

Review 9.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

10.  Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin.

Authors:  Anne-Cécile Huby; Maria-Pia Rastaldi; Kathleen Caron; Oliver Smithies; Jean-Claude Dussaule; Christos Chatziantoniou
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.